CRP2 emerges as a potential therapeutic target for breast cancer with a poor prognosis due to its dual role in promoting invadopodia formation in the cytoplasm and upregulating pro-invasive genes, including MMPs, in the nucleus. The gene discussed is CRIP2; the disease is breast carcinoma.